8-K: AVITA Medical Reports Record Second Quarter Revenue, Secures FDA Approval for RECELL GO

AVITA Medical announced a 29% increase in commercial revenue to $15.1 million for the second quarter of 2024, alongside key regulatory and partnership milestones.

Summary

• AVITA Medical reported a 29% increase in commercial revenue, reaching $15.1 million in the second quarter of 2024, compared to the same period in 2023.
• The company's gross profit margin improved to 86.2%, up from 81.2% in the prior year.
• The FDA approved the RECELL GO premarket approval supplement on May 29, 2024, with the first case completed on May 31, 2024.
• A PMA supplement for RECELL GO mini was submitted on June 28, 2024, and is expected to have a prioritized 180-day review period.
• AVITA Medical entered into an exclusive agreement with Regenity Biosciences for a collagen-based dermal matrix.
• The company expects Regenity to receive 510(k) clearance for the dermal matrix in the fourth quarter of 2024.
• Third-quarter 2024 commercial revenue is projected to be between $19.0 and $20.0 million, representing a 40% to 48% growth year-over-year.
• Full-year 2024 commercial revenue is now expected to be in the range of $68.0 to $70.0 million, reflecting a 37% to 41% growth over 2023.
• The company anticipates achieving cash flow break-even and GAAP profitability by the end of the third quarter of 2025.
• The net loss for the quarter was $15.4 million, or a loss of $0.60 per share, compared to a net loss of $10.4 million, or a loss of $0.41 per share, in the same period in 2023.
• As of June 30, 2024, AVITA Medical had approximately $54.1 million in cash, cash equivalents, and marketable securities.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, improved gross profit margins, key regulatory approvals, and strategic partnerships. While there is a net loss, the company's future outlook and growth trajectory are promising.

Positives

• The company achieved record commercial revenue of $15.1 million in the second quarter of 2024.
• The gross profit margin increased by 500 basis points to 86.2%.
• The FDA approved the RECELL GO device, expanding treatment capabilities.
• The company submitted a PMA supplement for RECELL GO mini, targeting smaller wounds.
• AVITA Medical secured an exclusive agreement with Regenity Biosciences for a new dermal matrix.
• The company anticipates strong revenue growth in the third quarter of 2024, with projections of $19.0 to $20.0 million.
• AVITA Medical is on track to achieve cash flow break-even and GAAP profitability by the end of the third quarter of 2025.

Negatives

• The company reported a net loss of $15.4 million for the second quarter of 2024, which is higher than the $10.4 million loss in the same period of 2023.
• Operating expenses increased to $28.7 million, up from $21.2 million in the same period in 2023, primarily due to increased sales and marketing costs.
• BARDA income decreased to zero, compared to $0.5 million in the prior year due to the ending of reimbursable clinical trials.
• Full-year revenue guidance was adjusted downward, although it still reflects a growth rate of over 37% year-over-year.

Risks

• The company's ability to achieve projected revenue growth is subject to market conditions and commercial execution.
• The company's profitability is dependent on controlling operating expenses and achieving revenue targets.
• Regulatory approvals for new products and technologies are subject to potential delays and uncertainties.
• The company's financial performance is subject to fluctuations in the fair value of warrant liability and debt.
• The company's success is dependent on the successful commercialization of new products and technologies.

Future Outlook

The company expects strong revenue growth in the third quarter of 2024 and anticipates achieving cash flow break-even and GAAP profitability by the end of the third quarter of 2025. They also plan to launch new products and conduct post-market clinical studies.

Management Comments

• Jim Corbett, Chief Executive Officer of AVITA Medical, stated that the second-quarter commercial revenue reflects the effectiveness of their enhanced focus on commercial execution.
• Jim Corbett also highlighted the FDA approval of RECELL GO and the submission of RECELL GO mini as progress in expanding treatment capabilities.
• David O'Toole, Chief Financial Officer of AVITA Medical, anticipates sequential third-quarter commercial revenue growth between 26% to 32% over the second quarter.
• David O'Toole also expressed confidence in the commercial team's ability to achieve the third-quarter revenue goal.

Industry Context

This announcement highlights AVITA Medical's continued growth in the regenerative medicine and wound care market. The FDA approvals and strategic partnerships position the company to expand its market share and address a broader range of clinical needs. The company's focus on innovative devices and technologies aligns with the industry's trend towards advanced wound care solutions.

Comparison to Industry Standards

• AVITA Medical's 29% year-over-year revenue growth in Q2 2024 is strong compared to the broader medical device industry, which typically sees single-digit growth rates.
• The gross profit margin of 86.2% is exceptionally high, indicating strong pricing power and efficient cost management, which is better than many comparable companies in the medical device sector.
• Companies like Integra LifeSciences and Smith & Nephew, which also operate in the wound care market, have gross margins in the 60-70% range, making AVITA's margin a significant differentiator.
• The FDA approval of RECELL GO and the submission of RECELL GO mini are significant milestones, positioning AVITA Medical as a leader in innovative wound care solutions, similar to how companies like Organogenesis have leveraged regulatory approvals to drive growth.
• The partnership with Regenity Biosciences is a strategic move to expand product offerings, similar to how companies like ACell have used partnerships to broaden their market reach.

Stakeholder Impact

• Shareholders will likely view the strong revenue growth and improved gross profit margin positively.
• Employees may benefit from the company's growth and expansion.
• Customers will have access to new and innovative wound care solutions.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company's financial performance as positive.

Next Steps

• Regenity is expected to receive 510(k) clearance for the dermal matrix in the fourth quarter of 2024.
• AVITA Medical will begin to market, sell, and distribute the dermal matrix following clearance.
• The company plans to initiate multiple post-market clinical studies to establish the synergies between the new dermal matrix and RECELL.
• The company anticipates FDA approval of RECELL GO mini by December 27, 2024.
• The company expects to submit both the post-market study (TONE) and a health care economics study for publication by year-end.

Key Dates

Keywords

RECELL, AVITA Medical, wound care, regenerative medicine, dermal matrix, FDA approval, commercial revenue, gross profit, financial results, RECELL GO, RECELL GO mini, Regenity Biosciences